12+

PHARMACOLOGICAL MANAGEMENT OF IMMUNE AND OXIDATIVE DISTURBANCES IN PATIENTS WITH ENCEPHALOPATHY ON THE BACKGROUND OF HYPERTENSION

Prior to treatment in patients with discirculatory encephalopathy stage II affected by hypertensive disease set at the system level elevation of proinflammatory and regulatory cytokines, stable metabolites of nitric oxide, a decrease of immunoglobulins M, G, A, disbalance of the complement system components, development oxidative stress. Inclusion of a comprehensive drug treatment of patients with discirculatory encephalopathy cerebrolysin combination with meksidol normalizes the concentration of C3 and C4 components of the complement system, IgG, malondialdehyde, catalase activity, total antioxidant activity of blood serum, corrects, but not to the level of standards, the contents of cytokines (TNF, IL-1β, IL-6, IL-8, IL-18, IFγ, IL-2, IL-17), complement component C5, IgA, acylhydrohyperoxide, neopterin and increases anti-inflammatory cytokines. Using emoxipine and piracetam as part of pharmacotherapy vascular encephalopathy stage II, compared with a combination of cerebrolysin and meksidol to further normalize levels of IL-17, C-reactive protein, increasingly closer to that of a control group of IL-6, IL-2 IL-18, C5, C5a component of complement, IgM, AGP, SMNO, increases the concentration of the complement system and cytokine network controllers. Included in the complex pharmacotherapy of patients with discirculatory encephalopathy and a combination aktovegin and cereton has maximum efficiency, normalizing 52% and 48% broken correlation immune parameters.

Иллюстрации

Figure 1. Changes in immune parameters in patients with discirculatory encephalopathy stage II affected by hypertensive disease before treatment.

Table 1. Change in the concentration of cytokines and complement system components in patients with stage II DEP affected by hypertensive disease in the application of neuroprotective combinations and antioxidant drugs (M±m; n=48)

Table 2. Immune efficacy of combinations neuroprotective and antioxidant drugs in patients with DEP (M±m; n=48)

DOI: 10.18413/2313-8971-2016-2-2-99-106
Количество просмотров: 2870 (смотреть статистику)
Количество скачиваний : 685
Полный текст (HTML)Полный текст (PDF)К списку статейВ раздел
  • Комментарии
  • Список литературы

Пока никто не оставил комментариев к этой публикации.
Вы можете быть первым.

Оставить комментарий: